Arbutus Biopharma
ABUS
71 hedge funds and large institutions have $158M invested in Arbutus Biopharma in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 8 closing their positions.
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
116% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $933K
72% more capital invested
Capital invested by funds: $91.9M → $158M (+$66.3M)
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
42% more funds holding
Funds holding: 50 → 71 (+21)
6.94% more ownership
Funds ownership: 33.37% → 40.32% (+6.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.1M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$6.94M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.89M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.76M |
| 5 |
Goldman Sachs
New York
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$2.68M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
-$1.45M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.43M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.04M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$777K |
ABUS Hedge Fund Activity: Q2 2018 in Review
71 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2018, worth a combined $158M — up 72% from $91.9M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ABUS positions and 8 closed out — a net gain of 21 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $10.1M. The largest seller was Axa, exiting entirely with an estimated $2.68M sold.
- 71 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2018, up from 50 in Q1 2018.
- Funds reported $158M of Arbutus Biopharma stock for Q2 2018, up 72% quarter-over-quarter.
- 29 funds opened new Arbutus Biopharma positions in Q2 2018 and 8 closed out, a net change of +21 holders.
- The largest Arbutus Biopharma buyer in Q2 2018 was BlackRock, an estimated $10.1M added.
- The largest Arbutus Biopharma seller in Q2 2018 was Axa, an estimated $2.68M sold.
Based on aggregated 13F filings for Q2 2018.